Inotek Pharmaceuticals Corp.

Inotek Pharmaceuticals Corp.

Inotek Pharmaceuticals Corp.

Overview
Date Founded

1999

Headquarters

91 Hartwell Avenue,2nd floor,Lexington, MA 02421

Type of Company

Private

Employees (Worldwide)

17

Industries

Pharmaceuticals
IT Consulting & Services
Retail: Drug Stores
Medical Support Services
Biotechnology

Company Description

Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA.

Executives & Employees

Chief Business Officer & Executive Vice President

Subscribe now to see full list of current and former executives
Paths to Inotek Pharmaceuticals Corp.
Potential Connections via
Relationship Science
You
Inotek Pharmaceuticals Corp.
Owners & Shareholders
Details Hidden

Risk Reward Capital Management Corp. is a hedge fund company located in Cambridge, Massachusetts

Details Hidden

Ghost Tree Capital LLC is a hedge fund manager located in New York City.

Details Hidden

Pura Vida Investments focuses on long/short equity investments in the healthcare and wellness sectors.

Subscribe now to see full details
Recent Transactions
Details Hidden

Inotek Pharmaceuticals Corp. issued Common Stock

Details Hidden

Inotek Pharmaceuticals Corp. issued Common Stock

Details Hidden

Inotek Pharmaceuticals Corp. raised money in a private placement transaction

Subscribe now to see full list of recent transations
Transaction Advisors
Escrow Agent

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Underwriter

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Legal Advisor

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Subscribe now to see 4+ more transaction advisors
Legal Advisor

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Chair, Life Sciences Practice

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Legal Advisor

Advised onInotek Pharmaceuticals Corp. issued Common Stock

Subscribe now to see transaction advisors for over 2.5 million organizations
Key Stats and Financials As of
Market Capitalization
$630M
Total Enterprise Value
Earnings Per Share
Subscribe now to see full financial details
Investors
Details Hidden

Director-Drug Development at Lovelace Respiratory Research Institute

Details Hidden

Co-Founder at Inotek Pharmaceuticals Corp.

Details Hidden

MedImmune Ventures focuses on discovering, developing and commercializing promising developments in the biotechnology products sector. The firm targets investments in areas with strategic potential for MedImmune LLC and AstraZeneca including: (1) cardiovascular disease (2) gastrointestinal disease (3) neuroscience (4) oncology (5) infectious diseases (6) respiratory disease and (7) inflammation.MedImmune Ventures invests in early- to late-stage, public or private biotechnology companies that discover and develop human therapeutics. They place particular emphasis on the fields of infectious disease, immunology and oncology. Their Funds are modality agnostic, investing in biologics, small molecules and vaccines. Investments range up to $30 million per company with average investments of about $7 million.

Subscribe now to see full details